Umaimah Naeem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Umaimah Naeem has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Mohsin Khan
Jinnah Sindh Medical University, Karachi, Pakistan
4 shared publications - Aminath Waafira
The Maldives National University
2 shared publications - Asma Azam
Department of Medicine, Karachi Medical and Dental College Karachi, Pakistan
2 shared publications - Erum Siddiqui
Jinnah Sindh Medical University, Karachi, Pakistan
2 shared publications - Maliha Khalid
Jinnah Sindh Medical University
2 shared publications Muhammad Mohsin Khan
Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan
2 shared publications
Latest Publications
- Open Access
- 25 February 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
Efficacy of recombinant human GM-CSF compared to placebo for autoimmune pulmonary alveolar proteinosis: a systematic review and meta-analysis
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare interstitial lung disease characterized by surfactant accumulation within alveoli due to impaire
- 25 February 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
Open AccessEfficacy of recombinant human GM-CSF compared to placebo for autoimmune pulmonary alveolar proteinosis: a systematic review and meta-analysis
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare interstitial lung disease characterized by surfactant accumulation within alveoli due to impaire
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Diabetes Research
- Vol. 2026 (1) , 5163895
Association Between Exercise and Brain‐Derived Neurotrophic Factor (BDNF) Levels in Diabetes Mellitus: A Systematic Review and Meta‐Analysis
Background: Diabetes mellitus (DM) is a metabolic disorder characterized by a consistently elevated blood sugar level. DM poses a major risk factor for many neurodegenerative diseases, causing a decline in cognitive function. BDNF (brain‐derived neurotrophic factor) is a neurotrophin in the central and peripheral nervous systems that plays a crucial role in the development of brain circuits. Hence, disturbance in levels of BDNF is linked to the occurrence of neurodegenerative diseases and cognitive decline in diabetic patients. Physical exercise has emerged as a nonpharmacological intervention in elevating BDNF levels. Our systematic review and meta‐analysis evaluate the relationship between a globally affecting metabolic disorder, diabetes, with decreased BDNF levels, and explore exercise as a promising potential intervention. Methods: After screening 37 articles, 4 studies have been included in the systematic review and meta‐analysis, out of which 3 of them are randomized controlled trials (RCTs), and 1 is a crossover trial. The search was conducted on PubMed (MEDLINE), ScienceDirect, Embase, Scopus, and Cochrane Central databases from inception to June 2025. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) guidelines were followed to conduct a systematic review. Cochrane risk‐of‐bias tool was used to assess the quality of the studies. Data were pooled using a random effect model. The protocol for this systematic review was registered in PROSPERO. Results: A total of 37 articles were screened, 3 RCTs and 1 crossover trial with 131 participants were included in the meta‐analysis. Serum BDNF levels were higher in the exercise group compared with controls (MD = 73.50; p = 0.05). A small reduction in body fat percentage in the exercise group compared with the control was found (MD = −1.24 % ; p = 0.17), which was not statistically significant. Body weight and fasting blood glucose (FBG) showed no statistically significant differences between the exercise and control groups (MD = 0.97; p = 0.65), (MD = −27.20; p = 0.31). Moderate to high heterogeneity was noticed across the data analyzed. Conclusion: This meta‐analysis overall concludes that regular exercise positively affects serum BDNF levels in diabetics. However, the small number of trials and small sample sizes has limited the conclusions. Further large‐scale RCTs are required to determine the long‐term neurological effects of exercise in diabetics.
- 1 January 2026
- Published by Wiley in Journal of Diabetes Research
- Vol. 2026 (1) , 5163895
Open AccessAssociation Between Exercise and Brain‐Derived Neurotrophic Factor (BDNF) Levels in Diabetes Mellitus: A Systematic Review and Meta‐Analysis
Background: Diabetes mellitus (DM) is a metabolic disorder characterized by a consistently elevated blood sugar level. DM poses a major risk factor for many neurodegenerative diseases, causing a decline in cognitive function. BDNF (brain‐derived neurotrophic factor) is a neurotrophin in the central and peripheral nervous systems that plays a crucial role in the development of brain circuits. Hence, disturbance in levels of BDNF is linked to the occurrence of neurodegenerative diseases and cognitive decline in diabetic patients. Physical exercise has emerged as a nonpharmacological intervention in elevating BDNF levels. Our systematic review and meta‐analysis evaluate the relationship between a globally affecting metabolic disorder, diabetes, with decreased BDNF levels, and explore exercise as a promising potential intervention. Methods: After screening 37 articles, 4 studies have been included in the systematic review and meta‐analysis, out of which 3 of them are randomized controlled trials (RCTs), and 1 is a crossover trial. The search was conducted on PubMed (MEDLINE), ScienceDirect, Embase, Scopus, and Cochrane Central databases from inception to June 2025. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) guidelines were followed to conduct a systematic review. Cochrane risk‐of‐bias tool was used to assess the quality of the studies. Data were pooled using a random effect model. The protocol for this systematic review was registered in PROSPERO. Results: A total of 37 articles were screened, 3 RCTs and 1 crossover trial with 131 participants were included in the meta‐analysis. Serum BDNF levels were higher in the exercise group compared with controls (MD = 73.50; p = 0.05). A small reduction in body fat percentage in the exercise group compared with the control was found (MD = −1.24 % ; p = 0.17), which was not statistically significant. Body weight and fasting blood glucose (FBG) showed no statistically significant differences between the exercise and control groups (MD = 0.97; p = 0.65), (MD = −27.20; p = 0.31). Moderate to high heterogeneity was noticed across the data analyzed. Conclusion: This meta‐analysis overall concludes that regular exercise positively affects serum BDNF levels in diabetics. However, the small number of trials and small sample sizes has limited the conclusions. Further large‐scale RCTs are required to determine the long‐term neurological effects of exercise in diabetics.
- Open Access
- 1 December 2025
- Published by Wiley in Microbiologyopen
- Vol. 14 (6) , e70166
A Systematic Review and Meta‐Analysis of Randomized Controlled Trials on the Benefits of Using Lactobacillus Supplements as an Adjunct Treatment for Helicobacter pylori Eradication
Supplementing H. pylori treatment with probiotics like Lactobacillus has become an essential approach due to the possible adverse effects of antibiotic therapy and the need to increase overall eradication rates. Although several types of Lactobacillus strains as probiotics were efficient in treating H. pylori , their relative efficiency in treating H. pylori was uncertain. A survey of databases, including PubMed, Cochrane, Google Scholar, Scopus, and Clinicaltrials.gov , retrieved 52 Randomized Controlled Trials (RCTs), with 14 meeting the criteria for RCTs on Lactobacillus supplementation (LS) as an adjunct therapy compared to placebo in adult H. pylori patients. Analyses were conducted using RevMan5.3, Cochrane Risk of Bias Tool, Comprehensive Meta‐Analysis Software, and GRADEpro. Fourteen RCTs, including 2054 patients with more than ten different probiotics, were included in this analysis. The LS group showed significantly higher H. pylori eradication rates [RR = 1.04 (95% CI: 1.01, 1.07; p = 0.009; I 2 = 0%); (high certainty)], decreased AEs including vomiting [RR = 0.82 (95% CI: 0.48, 1.41; p = 0.48; I 2 = 19%); (high certainty)], diarrhea [RR = 0.45 (95% CI: 0.26, 0.80; p = 0.007; I ² = 55%); (high certainty)], abdominal pain [RR = 0.73 (95% CI: 0.28, 1.93; p = 0.53; I ² = 66%); (high certainty)], anorexia [RR = 0.79 (95% CI: 0.23, 2.64; p = 0.70; I ² = 0%); (high certainty)], constipation [RR = 1.02 (95% CI: 0.42, 2.50; p = 0.96; I ² = 0%); (high certainty)], rash [RR = 1.51 (95% CI: 0.57, 3.98; p = 0.41; I ² = 0%); (high certainty)], taste disturbance [RR = 0.64 (95% CI: 0.44, 0.92; p = 0.02; I ² = 51%); (moderate certainty)], and reduction of gastrointestinal symptoms including abdominal pain [SMD = −0.19 (95% CI: −0.46, 0.09; p = 0.18; I² = %); (moderate certainty)]. None of the included RCTs depicted a high risk of bias. Lactobacillus added to triple or quadruple therapy increased eradication rates, but improvements in adverse effects and gastrointestinal symptoms were not significant. Multiple different strains limited assessment of individual effectiveness, preventing firm conclusions about the specific impact of each Lactobacillus type.
- 1 December 2025
- Published by Wiley in Microbiologyopen
- Vol. 14 (6) , e70166
Open AccessA Systematic Review and Meta‐Analysis of Randomized Controlled Trials on the Benefits of Using Lactobacillus Supplements as an Adjunct Treatment for Helicobacter pylori Eradication
Supplementing H. pylori treatment with probiotics like Lactobacillus has become an essential approach due to the possible adverse effects of antibiotic therapy and the need to increase overall eradication rates. Although several types of Lactobacillus strains as probiotics were efficient in treating H. pylori , their relative efficiency in treating H. pylori was uncertain. A survey of databases, including PubMed, Cochrane, Google Scholar, Scopus, and Clinicaltrials.gov , retrieved 52 Randomized Controlled Trials (RCTs), with 14 meeting the criteria for RCTs on Lactobacillus supplementation (LS) as an adjunct therapy compared to placebo in adult H. pylori patients. Analyses were conducted using RevMan5.3, Cochrane Risk of Bias Tool, Comprehensive Meta‐Analysis Software, and GRADEpro. Fourteen RCTs, including 2054 patients with more than ten different probiotics, were included in this analysis. The LS group showed significantly higher H. pylori eradication rates [RR = 1.04 (95% CI: 1.01, 1.07; p = 0.009; I 2 = 0%); (high certainty)], decreased AEs including vomiting [RR = 0.82 (95% CI: 0.48, 1.41; p = 0.48; I 2 = 19%); (high certainty)], diarrhea [RR = 0.45 (95% CI: 0.26, 0.80; p = 0.007; I ² = 55%); (high certainty)], abdominal pain [RR = 0.73 (95% CI: 0.28, 1.93; p = 0.53; I ² = 66%); (high certainty)], anorexia [RR = 0.79 (95% CI: 0.23, 2.64; p = 0.70; I ² = 0%); (high certainty)], constipation [RR = 1.02 (95% CI: 0.42, 2.50; p = 0.96; I ² = 0%); (high certainty)], rash [RR = 1.51 (95% CI: 0.57, 3.98; p = 0.41; I ² = 0%); (high certainty)], taste disturbance [RR = 0.64 (95% CI: 0.44, 0.92; p = 0.02; I ² = 51%); (moderate certainty)], and reduction of gastrointestinal symptoms including abdominal pain [SMD = −0.19 (95% CI: −0.46, 0.09; p = 0.18; I² = %); (moderate certainty)]. None of the included RCTs depicted a high risk of bias. Lactobacillus added to triple or quadruple therapy increased eradication rates, but improvements in adverse effects and gastrointestinal symptoms were not significant. Multiple different strains limited assessment of individual effectiveness, preventing firm conclusions about the specific impact of each Lactobacillus type.
- Open Access
- 24 November 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (12) , e71036
Safety and Efficacy of Eslicarbazepine Acetate in Children Diagnosed With a Focal Seizure Disorder: A Systematic Review and Meta‐Analysis
Background: Epilepsy can have a negative impact on cognitive and social functioning. Eslicarbazepine acetate (ESL) is used to treat focal seizures, although its safety and efficacy, particularly as an additional treatment, warrant more study. The purpose of this study was to evaluate the safety and efficacy of ESL in children with focal seizures by analyzing data from relevant clinical trials. Methods: This study was conducted in line with the PRISMA guidelines and has been registered on the PROSPERO 2024 CRD42024569119 register. A detailed search up to July 2024 through Cochrane CENTRAL, PubMed/MEDLINE, and Google Scholar was conducted for the studies comparing ESL with placebo. For the meta‐analysis, the Mantel–Haenszel random‐effects model was applied, and heterogeneity was measured using the I 2 index. Results: The study included a total of 742 children from the randomized controlled trials; of these, 414 were given ESL, whereas 328 were given a placebo. ESL significantly reduced seizure frequency when compared to placebo (SMD = −0.29; 95% CI [−0.57, −0.02]). Nevertheless, it has been related to a greater risk of side effects, including headaches, sleepiness, nausea, vomiting, double vision, and dizziness. Adverse events were measured to evaluate clinical significance. Treatment‐emergent‐related adverse events (TEAEs) occurred in 52.2% of ESL‐treated participants versus 49.1% in placebo individuals (RR = 1.08; 95% CI [0.96–1.20]; p = 0.20), indicating no statistically significant increase overall. However, specific adverse events were significantly more common with ESL, including somnolence: RR = 1.95; 95% CI (1.11–3.43); p = 0.02 and diplopia: RR = 4.34; 95% CI (1.60–11.78); p = 0.004. Other common but nonsignificant adverse events included headache (11.49%), vomiting (6.15%), nausea (3.34%), and dizziness (3.2%). Adverse event‐related treatment discontinuation was reported in 5.2%–5.9% of ESL patients compared to 2.3%–2.5% of placebo patients. Most adverse events were mild to severe, although serious adverse events (e.g., status epilepticus, device‐related problems) were more common in the ESL group. Conclusion: Though ESL increases the risk of adverse effects, it dramatically reduces seizure frequency in children with focal epilepsy. These risks require regular monitoring. Subsequent study should focus on long‐term effectiveness, safety, and ways to mitigate the negative effects of ESL.
- 24 November 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (12) , e71036
Open AccessSafety and Efficacy of Eslicarbazepine Acetate in Children Diagnosed With a Focal Seizure Disorder: A Systematic Review and Meta‐Analysis
Background: Epilepsy can have a negative impact on cognitive and social functioning. Eslicarbazepine acetate (ESL) is used to treat focal seizures, although its safety and efficacy, particularly as an additional treatment, warrant more study. The purpose of this study was to evaluate the safety and efficacy of ESL in children with focal seizures by analyzing data from relevant clinical trials. Methods: This study was conducted in line with the PRISMA guidelines and has been registered on the PROSPERO 2024 CRD42024569119 register. A detailed search up to July 2024 through Cochrane CENTRAL, PubMed/MEDLINE, and Google Scholar was conducted for the studies comparing ESL with placebo. For the meta‐analysis, the Mantel–Haenszel random‐effects model was applied, and heterogeneity was measured using the I 2 index. Results: The study included a total of 742 children from the randomized controlled trials; of these, 414 were given ESL, whereas 328 were given a placebo. ESL significantly reduced seizure frequency when compared to placebo (SMD = −0.29; 95% CI [−0.57, −0.02]). Nevertheless, it has been related to a greater risk of side effects, including headaches, sleepiness, nausea, vomiting, double vision, and dizziness. Adverse events were measured to evaluate clinical significance. Treatment‐emergent‐related adverse events (TEAEs) occurred in 52.2% of ESL‐treated participants versus 49.1% in placebo individuals (RR = 1.08; 95% CI [0.96–1.20]; p = 0.20), indicating no statistically significant increase overall. However, specific adverse events were significantly more common with ESL, including somnolence: RR = 1.95; 95% CI (1.11–3.43); p = 0.02 and diplopia: RR = 4.34; 95% CI (1.60–11.78); p = 0.004. Other common but nonsignificant adverse events included headache (11.49%), vomiting (6.15%), nausea (3.34%), and dizziness (3.2%). Adverse event‐related treatment discontinuation was reported in 5.2%–5.9% of ESL patients compared to 2.3%–2.5% of placebo patients. Most adverse events were mild to severe, although serious adverse events (e.g., status epilepticus, device‐related problems) were more common in the ESL group. Conclusion: Though ESL increases the risk of adverse effects, it dramatically reduces seizure frequency in children with focal epilepsy. These risks require regular monitoring. Subsequent study should focus on long‐term effectiveness, safety, and ways to mitigate the negative effects of ESL.
- Open Access
- 12 November 2025
- Published by SAGE Publications in Therapeutic Advances in Cardiovascular Disease
- Vol. 19
Neurological efficacy and safety of RNA therapeutics in hereditary transthyretin amyloidosis: a systematic review and meta-analysis of randomized controlled trials
Background: Hereditary transthyretin amyloidosis (hATTR) is caused by mutations in the transthyretin (TTR) gene, which lead to the aggregation of misfolded TTR protein and amyloid accumulation in the peripheral nerves, heart, and gastrointestinal tract. Recently, RNA therapeutics, including small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs), have been approved for treating patients with hATTR. Objectives: To assess the neurological efficacy and safety of RNA therapeutics in hATTR patients. Design: Systematic review and meta-analysis. Data sources and methods: A systematic literature search was conducted on PubMed, Cochrane, and ClinicalTrials.gov from inception to August 14, 2024. Outcomes included changes from baseline in the Norfolk Quality of Life–Diabetic Neuropathy (Norfolk QOL-DN) score and the modified Neuropathy Impairment Score +7 (mNIS + 7), modified body mass index (mBMI), adverse effects, serious adverse events, and all-cause mortality. Results: Our study included four RCTs with 842 patients (568 in the RNA therapeutics group and 274 in the placebo group). RNA therapeutics significantly improved Norfolk QoL-DN (mean difference (MD), −18.79; 95% CI, −22.32 to −15.25; p < 0.00001; I 2 = 28%) and mNIS + 7 scores (MD, −26.90; 95% CI, −31.67 to −22.13; p < 0.00001; I 2 = 61%), with significant preservation of mBMI (MD, 114.98; 95% CI, 90.64–139.32; p < 0.00001; I 2 = 59%) compared to placebo. There were no significant differences between the two groups regarding the risk of adverse effects (risk ratio (RR), 0.89; 95% CI, 0.69–1.15; p = 0.36; I 2 = 34%), serious adverse effects (RR, 0.70; 95% CI, 0.31–1.58; p = 0.39; I 2 = 20%), and all-cause mortality (RR, 0.70; 95% CI, 0.31 to 1.58; p = 0.39; I 2 = 20%). Conclusion: RNA therapeutics are effective and well-tolerated in patients with hATTR, significantly improving quality of life and the progression of neurological impairment. siRNAs demonstrate better outcomes compared to ASOs. Trial registration: PROSPERO (CRD42024568346).
- 12 November 2025
- Published by SAGE Publications in Therapeutic Advances in Cardiovascular Disease
- Vol. 19
Open AccessNeurological efficacy and safety of RNA therapeutics in hereditary transthyretin amyloidosis: a systematic review and meta-analysis of randomized controlled trials
Background: Hereditary transthyretin amyloidosis (hATTR) is caused by mutations in the transthyretin (TTR) gene, which lead to the aggregation of misfolded TTR protein and amyloid accumulation in the peripheral nerves, heart, and gastrointestinal tract. Recently, RNA therapeutics, including small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs), have been approved for treating patients with hATTR. Objectives: To assess the neurological efficacy and safety of RNA therapeutics in hATTR patients. Design: Systematic review and meta-analysis. Data sources and methods: A systematic literature search was conducted on PubMed, Cochrane, and ClinicalTrials.gov from inception to August 14, 2024. Outcomes included changes from baseline in the Norfolk Quality of Life–Diabetic Neuropathy (Norfolk QOL-DN) score and the modified Neuropathy Impairment Score +7 (mNIS + 7), modified body mass index (mBMI), adverse effects, serious adverse events, and all-cause mortality. Results: Our study included four RCTs with 842 patients (568 in the RNA therapeutics group and 274 in the placebo group). RNA therapeutics significantly improved Norfolk QoL-DN (mean difference (MD), −18.79; 95% CI, −22.32 to −15.25; p < 0.00001; I 2 = 28%) and mNIS + 7 scores (MD, −26.90; 95% CI, −31.67 to −22.13; p < 0.00001; I 2 = 61%), with significant preservation of mBMI (MD, 114.98; 95% CI, 90.64–139.32; p < 0.00001; I 2 = 59%) compared to placebo. There were no significant differences between the two groups regarding the risk of adverse effects (risk ratio (RR), 0.89; 95% CI, 0.69–1.15; p = 0.36; I 2 = 34%), serious adverse effects (RR, 0.70; 95% CI, 0.31–1.58; p = 0.39; I 2 = 20%), and all-cause mortality (RR, 0.70; 95% CI, 0.31 to 1.58; p = 0.39; I 2 = 20%). Conclusion: RNA therapeutics are effective and well-tolerated in patients with hATTR, significantly improving quality of life and the progression of neurological impairment. siRNAs demonstrate better outcomes compared to ASOs. Trial registration: PROSPERO (CRD42024568346).
- 24 September 2025
- Published by Elsevier in American Heart Journal
- Vol. 291, 213
Letter to the editor: Loop and thiazide diuretics and outcomes in heart failure with preserved ejection fraction
- 24 September 2025
- Published by Elsevier in American Heart Journal
- Vol. 291, 213
Letter to the editor: Loop and thiazide diuretics and outcomes in heart failure with preserved ejection fraction
- Open Access
- 1 August 2025
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 31
Efficacy of Factor Xa Inhibitors Versus Placebo in Thromboprophylaxis for Cancer-Associated Thromboembolism: A Systematic Review and Meta-analysis
Background: Cancer patients are at significantly increased risk of venous thromboembolism (VTE), a leading cause of morbidity and mortality in this population. While traditional anticoagulants like low-molecular-weight heparin (LMWH) and vitamin K antagonists (VKAs) are commonly used, their limitations have prompted growing interest in direct oral anticoagulants (DOACs), particularly Factor Xa inhibitors. However, concerns about bleeding risks persist. This meta-analysis aims to evaluate the efficacy of Factor Xa inhibitors versus placebo for thromboprophylaxis in cancer-associated VTE. Methods: This systematic review and meta-analysis followed PRISMA guidelines and was registered with PROSPERO (CRD42024574869). A comprehensive search of PubMed, Cochrane Library, Scopus, Google Scholar, and ClinicalTrials.gov was conducted without language or demographic restrictions. Data were extracted independently by two reviewers and analyzed using a random-effects model. Results: Six RCTs with a total of 2330 participants met the inclusion criteria. The pooled analysis showed a non-significant reduction in VTE incidence with Factor Xa inhibitors (RR = 0.33, 95% CI: 0.05-2.10, P = .24). However, there was a nearly twofold increased risk of major bleeding (RR = 1.90, 95% CI: 1.00-3.62, P = .05). No significant effect was found for clinically relevant non-major bleeding (CRNMB) (RR = 1.28, 95% CI: 0.73-2.22, P = .39). Conclusion: Factor Xa inhibitors may reduce the risk of VTE in cancer patients but appear to increase the risk of major bleeding. The evidence remains inconclusive due to limited event numbers and wide confidence intervals, highlighting the need for larger trials to better assess safety and efficacy.
- 1 August 2025
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 31
Open AccessEfficacy of Factor Xa Inhibitors Versus Placebo in Thromboprophylaxis for Cancer-Associated Thromboembolism: A Systematic Review and Meta-analysis
Background: Cancer patients are at significantly increased risk of venous thromboembolism (VTE), a leading cause of morbidity and mortality in this population. While traditional anticoagulants like low-molecular-weight heparin (LMWH) and vitamin K antagonists (VKAs) are commonly used, their limitations have prompted growing interest in direct oral anticoagulants (DOACs), particularly Factor Xa inhibitors. However, concerns about bleeding risks persist. This meta-analysis aims to evaluate the efficacy of Factor Xa inhibitors versus placebo for thromboprophylaxis in cancer-associated VTE. Methods: This systematic review and meta-analysis followed PRISMA guidelines and was registered with PROSPERO (CRD42024574869). A comprehensive search of PubMed, Cochrane Library, Scopus, Google Scholar, and ClinicalTrials.gov was conducted without language or demographic restrictions. Data were extracted independently by two reviewers and analyzed using a random-effects model. Results: Six RCTs with a total of 2330 participants met the inclusion criteria. The pooled analysis showed a non-significant reduction in VTE incidence with Factor Xa inhibitors (RR = 0.33, 95% CI: 0.05-2.10, P = .24). However, there was a nearly twofold increased risk of major bleeding (RR = 1.90, 95% CI: 1.00-3.62, P = .05). No significant effect was found for clinically relevant non-major bleeding (CRNMB) (RR = 1.28, 95% CI: 0.73-2.22, P = .39). Conclusion: Factor Xa inhibitors may reduce the risk of VTE in cancer patients but appear to increase the risk of major bleeding. The evidence remains inconclusive due to limited event numbers and wide confidence intervals, highlighting the need for larger trials to better assess safety and efficacy.
- Open Access
- 5 June 2025
- Published by SAGE Publications in Therapeutic Advances in Vaccines and Immunotherapy
- Vol. 13
Evaluating the immunogenicity and safety of ID93 + GLA-SE in BCG-vaccinated healthy adults: a systematic review and meta-analysis of randomized controlled trials
Background: Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is an ancient disease that continues to pose a significant threat to global public health. Although the BCG vaccine, developed in the 1920s, remains the only approved TB vaccine, it has limited efficacy, particularly against pulmonary TB in adults. The ID93/GLA-SE vaccine, a recombinant subunit vaccine, shows promise by triggering immune solid responses and could be a key solution in combating TB, particularly in the face of rising drug-resistant strains and suboptimal current vaccines. It has the potential to address the unmet need for more effective interventions against drug-resistant TB, a growing global health issue that continues to challenge existing treatment options. Objective: To evaluate the immunogenicity and safety of ID93 + GLA-SE in BCG-vaccinated healthy adults. Methods: A comprehensive electronic search on PubMed (Medline), ScienceDirect, EMBASE, Scopus, and Cochrane Central database was conducted from inception till August 2024 for randomized controlled trials (RCTs) with a target population of BCG-vaccinated healthy adults. This review was conducted according to (PRISMA) criteria and registered with PROSPERO (CRD42024601450). This meta-analysis used Review Manager and forest plots for visual display. The outcomes were displayed as risk ratios (RR) with a 95% confidence interval. Results: The ID93 + GLA-SE vaccine showed strong immunogenicity, particularly in high doses, with robust IgG responses sustained up to day 421 in all studies, significantly higher than baseline, and seroconversion rates remained high through day 84. CD4 T-cell responses peaked after the third dose and remained elevated through day 421, whereas CD8 T-cell responses were minimal. Regarding adverse effects, the ID93 + GLA-SE vaccine significantly increases fatigue (RR 3.24, p = 0.005), myalgia (RR 5.82, p < 0.0001), and injection site pain (RR 4.12, p < 0.00001), compared to placebo, with consistent results across both high and low doses. However, there were no significant differences for upper respiratory tract infections, 0.83 (95% CI 0.38–1.84, p = 0.87) or 1.77 (95% CI 0.77–4.10, p = 0.18) headaches. Dose optimization remains crucial due to the higher side effect risks of increased doses. Conclusion: The ID93 + GLA-SE vaccine shows a solid safety profile and enhances immune responses, especially IgG and CD4+ T-cell activity, which is crucial for TB defense. Higher doses improve efficacy but increase side effects, highlighting the need for dose optimization. As a potential alternative to the BCG vaccine, especially in drug-resistant TB regions, further research should refine dosage and assess long-term safety.
- 5 June 2025
- Published by SAGE Publications in Therapeutic Advances in Vaccines and Immunotherapy
- Vol. 13
Open AccessEvaluating the immunogenicity and safety of ID93 + GLA-SE in BCG-vaccinated healthy adults: a systematic review and meta-analysis of randomized controlled trials
Background: Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is an ancient disease that continues to pose a significant threat to global public health. Although the BCG vaccine, developed in the 1920s, remains the only approved TB vaccine, it has limited efficacy, particularly against pulmonary TB in adults. The ID93/GLA-SE vaccine, a recombinant subunit vaccine, shows promise by triggering immune solid responses and could be a key solution in combating TB, particularly in the face of rising drug-resistant strains and suboptimal current vaccines. It has the potential to address the unmet need for more effective interventions against drug-resistant TB, a growing global health issue that continues to challenge existing treatment options. Objective: To evaluate the immunogenicity and safety of ID93 + GLA-SE in BCG-vaccinated healthy adults. Methods: A comprehensive electronic search on PubMed (Medline), ScienceDirect, EMBASE, Scopus, and Cochrane Central database was conducted from inception till August 2024 for randomized controlled trials (RCTs) with a target population of BCG-vaccinated healthy adults. This review was conducted according to (PRISMA) criteria and registered with PROSPERO (CRD42024601450). This meta-analysis used Review Manager and forest plots for visual display. The outcomes were displayed as risk ratios (RR) with a 95% confidence interval. Results: The ID93 + GLA-SE vaccine showed strong immunogenicity, particularly in high doses, with robust IgG responses sustained up to day 421 in all studies, significantly higher than baseline, and seroconversion rates remained high through day 84. CD4 T-cell responses peaked after the third dose and remained elevated through day 421, whereas CD8 T-cell responses were minimal. Regarding adverse effects, the ID93 + GLA-SE vaccine significantly increases fatigue (RR 3.24, p = 0.005), myalgia (RR 5.82, p < 0.0001), and injection site pain (RR 4.12, p < 0.00001), compared to placebo, with consistent results across both high and low doses. However, there were no significant differences for upper respiratory tract infections, 0.83 (95% CI 0.38–1.84, p = 0.87) or 1.77 (95% CI 0.77–4.10, p = 0.18) headaches. Dose optimization remains crucial due to the higher side effect risks of increased doses. Conclusion: The ID93 + GLA-SE vaccine shows a solid safety profile and enhances immune responses, especially IgG and CD4+ T-cell activity, which is crucial for TB defense. Higher doses improve efficacy but increase side effects, highlighting the need for dose optimization. As a potential alternative to the BCG vaccine, especially in drug-resistant TB regions, further research should refine dosage and assess long-term safety.
- Open Access
- 28 March 2025
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 25 (1) , 1-14
Evaluating comparative effectiveness of pembrolizumab-based therapy versus chemotherapy in treatment of gastric carcinoma: a systematic review and meta-analysis of randomized controlled trials
Gastric cancer, especially cancer of the gastro-esophageal junction, ranks among the first five cancers in the world with the highest mortality rates. It has poor survival rates for the advanced stages. Traditional chemotherapy, while standard, often results in significant side effects and limited efficacy. The objective of this meta-analysis and systemic review is to ascertain if pembrolizumab-based therapies for advanced gastric cancer are more effective and safer than standard chemotherapy. The focus consisted of RCTs with adults suffering from gastric carcinoma who received pembrolizumab every 3 weeks (200 mg) intra-related dose or with at least comparable chemotherapy regimen. Outcomes assessed are as follows: overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). All potential sources regarding the search of outcome measures were applied: Google Scholar, Scopus, PubMed, and Cochrane library, and last search in June 2024 was carried out. Out of 568 articles screened, four RCTs comprising 2,831 patients met the inclusion criteria. Analysis indicated that pembrolizumab alone did not significantly improve OS compared to chemotherapy (HR 0.87). However, when combined with chemotherapy, pembrolizumab dramatically enhanced OS (HR 0.80) and PFS (HR 0.78). ORR was superior in the pembrolizumab plus chemotherapy group (RR 1.24), while pembrolizumab monotherapy showed no significant difference from chemotherapy alone. Safety analysis revealed a higher frequency of adverse events in the pembrolizumab-based therapy groups compared to chemotherapy. Pembrolizumab together with chemotherapy improves greater survival and higher levels of response rate in patients with severe gastric cancer, especially with high PD-L1 expression. But it has rather more adverse events, allowing patient monitoring with care.
- 28 March 2025
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 25 (1) , 1-14
Open AccessEvaluating comparative effectiveness of pembrolizumab-based therapy versus chemotherapy in treatment of gastric carcinoma: a systematic review and meta-analysis of randomized controlled trials
Gastric cancer, especially cancer of the gastro-esophageal junction, ranks among the first five cancers in the world with the highest mortality rates. It has poor survival rates for the advanced stages. Traditional chemotherapy, while standard, often results in significant side effects and limited efficacy. The objective of this meta-analysis and systemic review is to ascertain if pembrolizumab-based therapies for advanced gastric cancer are more effective and safer than standard chemotherapy. The focus consisted of RCTs with adults suffering from gastric carcinoma who received pembrolizumab every 3 weeks (200 mg) intra-related dose or with at least comparable chemotherapy regimen. Outcomes assessed are as follows: overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). All potential sources regarding the search of outcome measures were applied: Google Scholar, Scopus, PubMed, and Cochrane library, and last search in June 2024 was carried out. Out of 568 articles screened, four RCTs comprising 2,831 patients met the inclusion criteria. Analysis indicated that pembrolizumab alone did not significantly improve OS compared to chemotherapy (HR 0.87). However, when combined with chemotherapy, pembrolizumab dramatically enhanced OS (HR 0.80) and PFS (HR 0.78). ORR was superior in the pembrolizumab plus chemotherapy group (RR 1.24), while pembrolizumab monotherapy showed no significant difference from chemotherapy alone. Safety analysis revealed a higher frequency of adverse events in the pembrolizumab-based therapy groups compared to chemotherapy. Pembrolizumab together with chemotherapy improves greater survival and higher levels of response rate in patients with severe gastric cancer, especially with high PD-L1 expression. But it has rather more adverse events, allowing patient monitoring with care.
- Open Access
- 19 March 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (4) , 2286-2294
Clinical and surgical outcomes of virginal breast hypertrophy (VBH) in adolescent females: a systematic review of case reports
Background: The rare medical condition known as Virginal Breast Hypertrophy causes massive adolescent breast growth that leads to the important health problems with social implications. This systematic review examines treatment procedures and psychological effects along with identifying remaining knowledge gaps regarding this disorder. Methods: The research team executed a PRISMA-based literature search covering cases from the year 1934 to 2023, and analyzed 69 cases of VBH. The analysis included information about symptoms at diagnosis and treatment methods along with the recurrence rates and details about psychological elements. The study included patients who experienced juvenile breast hypertrophy during adolescence. Results: VBH typically presented with rapid bilateral breast enlargement (91.3%) and psychological distress (71%). The mean age of onset was 11.27 years, with disease progression averaging 10 months. Menarche was documented in 43.75%. Subcutaneous mastectomy showed the lowest recurrence rate (5.8%), while reduction mammoplasty had a recurrence rate of 44.7%. Medical treatments (e.g., tamoxifen, bromocriptine) showed variable outcomes, with most patients exhibiting no hormonal abnormalities. Conclusions: Among breast cancer treatments subcutaneous mastectomy stands as the most successful method that results in few recurrences. Documentation of psychological distress created by VBH demands collaborative care strategies and extensive investigations into genetic molecular influences.
- 19 March 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (4) , 2286-2294
Open AccessClinical and surgical outcomes of virginal breast hypertrophy (VBH) in adolescent females: a systematic review of case reports
Background: The rare medical condition known as Virginal Breast Hypertrophy causes massive adolescent breast growth that leads to the important health problems with social implications. This systematic review examines treatment procedures and psychological effects along with identifying remaining knowledge gaps regarding this disorder. Methods: The research team executed a PRISMA-based literature search covering cases from the year 1934 to 2023, and analyzed 69 cases of VBH. The analysis included information about symptoms at diagnosis and treatment methods along with the recurrence rates and details about psychological elements. The study included patients who experienced juvenile breast hypertrophy during adolescence. Results: VBH typically presented with rapid bilateral breast enlargement (91.3%) and psychological distress (71%). The mean age of onset was 11.27 years, with disease progression averaging 10 months. Menarche was documented in 43.75%. Subcutaneous mastectomy showed the lowest recurrence rate (5.8%), while reduction mammoplasty had a recurrence rate of 44.7%. Medical treatments (e.g., tamoxifen, bromocriptine) showed variable outcomes, with most patients exhibiting no hormonal abnormalities. Conclusions: Among breast cancer treatments subcutaneous mastectomy stands as the most successful method that results in few recurrences. Documentation of psychological distress created by VBH demands collaborative care strategies and extensive investigations into genetic molecular influences.